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Abstract 
Examining the Effect of Tumor Features, BDNF, and 5-HTT Genotypes on Depressive 
Symptoms in Breast Cancer 
 
Justine Wang, BSN 
 
University of Pittsburgh, 2019 
 
 
The development of depressive symptoms in women with breast cancer is multifactorial 
and may be impacted by both genetics and pathologic tumor features. The purpose of this study is 
to examine the contributions of the serotonin transporter (SERT) and brain-derived neurotrophic 
factor (BDNF) genes to the development of depressive symptoms in postmenopausal women with 
early-stage breast cancer. Another aim is to investigate the impact of pathologic tumor features on 
the development of depressive symptoms. N=258 women (n=162 women with breast cancer and 
n=96 matched healthy controls) were included in the genetic aims of this study, and N=329 women 
with breast cancer were included in the pathologic tumor features analysis. Depressive 
symptomology was measured using the Beck Depression Inventory (BDI – II) at baseline, and six 
months and 12 months post-baseline. Linear and logistic regression models were built both with 
and without control for treatment group as a predictor. Participants with a SERT genotype of LA/LA 
had significantly higher mean BDI-II scores across time compared to all other SERT genotypes. 
No significant associations were found between BDNF genotype and depressive symptoms. A 
high Ki67 classification was associated with decreased depressive symptoms, while multifocal 
tumors and increased HER2 classification were associated with increased depressive symptoms. 
Our results support a previous study conducted at the University of Pittsburgh School of Nursing 
suggesting that the LA allele is a risk factor for depressive symptoms in women with breast cancer. 
In addition, pathologic tumor features that have previously been associated with poorer cognitive 
performance were similarly implicated in depressive symptom development.  
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1.0 Background 
1.1 Depression 
Depression is a mood state characterized by sadness, despair, and hopelessness (1). 
Depressive symptoms interfere with quality of life, are associated with negative outcomes such as 
suicide (2), and include loss of pleasure in activities, sleep disturbances, fatigue, and cognitive 
deficits in concentration and decision-making. Depression can be a component of more serious 
mood disorders including major depressive disorder (MDD). Between 2005 and 2010 in the United 
States, the prevalence of MDD increased from 13.8 to 15.4 million adults, and healthcare costs 
due to MDD increased to $210.5 billion per year (3). The Center for Behavioral Health Statistics 
and Quality found that 20.7% of adults experience a major depressive episode in their lifetime (4).  
The development of depression is complex and involves genetic, environmental, and 
physiological factors. Recent research has focused on contributions from risk genes, epigenetic 
regulation of gene expression, and shorter telomere length in DNA (5-7). Environmental factors 
such as low birth weight, prematurity, trauma, stress, and decreased social support are associated 
with depression, as well (8-9). Biological factors associated with depression include increased 
inflammation and decreased activity of certain neurotransmitters (10). Females experience single 
and recurrent depressive disorders at a rate almost twice that of males (11) and the risk of 
developing both short-term and long-term depression increases following the experience of a 
stressful life event. In this study, subjects have experienced a stressful life event, which we have 
identified as the diagnosis and treatment of breast cancer (12). 
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1.2 Breast Cancer 
Breast cancer is the most common cancer occurring in women (13). In the United States 
this year, about 330,000 women will receive a new diagnosis of breast cancer and about 80% of 
these cases will be an invasive type (13). Additionally, there is a large number of breast cancer 
survivors (over 3.1 million) who are still undergoing or have completed treatment (13). A recent 
study followed women recently diagnosed with breast cancer and found that 16.6% exhibited 
symptoms indicating a major depressive episode at least once over a period of 12 months (14). 
This incidence is disproportionately high when compared to the general female population, which 
has a 12-month prevalence of depression of 8.4% (15). One study of older women with breast 
cancer found that depressive symptoms increased the most within the first six months after 
diagnosis (16). Depressive symptoms in women with breast cancer should be seriously considered 
as they are strongly correlated with increased mortality (17). In survivors, depression can affect 
quality of life by contributing to poor health outcomes, such as decreased screening for other 
cancers (18) and barriers to physical activity and healthy eating (19). 
1.3 Serotonin Transporter 
Serotonin is a monoamine neurotransmitter responsible for various functions due to the 
widespread distribution of serotonin receptors in the body. Most of the body’s serotonin is 
concentrated in the gastrointestinal tract, where serotonin is involved in liver regeneration, 
gastrointestinal motility, and appetite (20). Serotonin also has important cardiovascular effects, 
contributing to blood vessel constriction and dilation, blood pressure, and heart rate (20). 
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Furthermore, serotonin activity in the central nervous system has a role in aggression, anxiety, 
memory, mood, sleep, learning, and addictive behaviors (20). Deficiency of serotonin is implicated 
in the monoamine hypothesis of depression, which explains the development of depression as a 
result of neurotransmitter deficiency. The monoamine hypothesis is the basis for antidepressant 
medications that inhibit the reuptake of serotonin and therefore potentiate its effects in the neuronal 
synapse (21). 
The SLC6A4 gene expresses the serotonin transporter protein (5-HTT), which is 
responsible for the return of serotonin from the synapse to the presynaptic neuron during reuptake 
(22). A 44 base-pair insertion/deletion functional polymorphism in the promoter region of SLC6A4 
is known as the serotonin-transporter-linked polymorphic region (5-HTTLPR) and has been a 
major subject of focus regarding the role of serotonin transporter in depression. Two common 
versions of the 5-HTTLPR polymorphism consist of the long “L”-allele (insertion) and the short 
“S”-allele (deletion). The L-allele is associated with increased serotonin transporter expression 
(and, thus, serotonin reuptake), while the S-allele is associated with decreased serotonin transporter 
expression and serotonin reuptake (23). In other words, the L-allele results in higher serotonin 
transporter activity, while the S-allele results in lower serotonin transporter activity. In addition, 
SLC6A4 displays a single nucleotide polymorphism called rs25531 (SNP, rs25531 A>G) that is 
found exclusively within the L-allele. The L-allele has an adenine (A) base which is substituted 
for guanine (G) in the polymorphism, resulting in the variant LG-allele functioning more like the 
S-allele than the original LA-allele (24). 
Results in the literature are inconsistent regarding the relationship of serotonin transporter 
genotype and severity of depressive symptoms. Recently, a study of women with advanced breast 
cancer demonstrated that the S-allele was associated with greater depressive symptoms (25). In 
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another study, anxious and depressive symptoms were shown to persist longer in women with 
breast cancer who have one or two S-alleles compared to two LA alleles, suggesting that the LA/LA 
genotype has a beneficial role in coping with mental distress (26). In women with breast cancer 
who experienced altered body image and reduced sexual function, the S-allele was associated with 
severity of depressive symptoms (27). On the other hand, the results of a study of women in the 
early postoperative period after breast cancer surgery suggest that some patients with the LA/LA 
genotype may be at greater risk for depressive symptoms and a sense of hopelessness (28). In a 
study by Rawson et al. (2015) of older adults who experienced a recent hip fracture (which was 
deemed a stressful event), participants with the LA/LA genotype had increased depressive 
symptoms compared to all other participants (29).  
Recent studies of women with breast cancer (Table 1) have not included the rs25531 single-
nucleotide polymorphism in analysis or have not had available subjects with the variant LG-allele. 
In addition, none of the studies included comparison with healthy controls. A study (N=125) by 
University of Pittsburgh School of Nursing faculty included n=19 subjects with breast cancer with 
the LG-allele as well as n=45 healthy controls. This study demonstrated that the LA/LA genotype 
was associated with increased depressive symptoms among the overall sample, though there was 
no statistically significant relationship between genotype and depressive symptoms among only 
women with breast cancer (30). 
Table 1 Literature Regarding SERT Risk Polymorphisms In Women with Breast Cancer 
 Schillani, 
G., 
Martinis, 
E., 
Capozzo, 
M.A.,… 
(2010) 
Schillani, 
G., Era, D., 
Cristante, 
T.,… 
(2012) 
Kim, K.R., 
Chung, H.C., 
Lee, E.,… 
(2012) 
Kim, Y., Carver, 
C.S., Hallmayer, 
J.F,… (2018) 
Wang, J., 
Bender, C.M., 
Conley, 
Y.P.,… (2018) 
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LG allele Not 
studied 
No 
available 
subjects 
Not studied Not studied N=19 
Sample 
size? 
53  48 186 95 125  
Healthy 
controls 
no no no no N= 45 
Depression 
measure 
Hospital 
Anxiety 
and 
Depression 
Scale  
Hospital 
Anxiety 
and 
Depression 
Scale 
Hospital 
Anxiety and 
Depression 
Scale, 
Hamilton 
Depression 
Rating Scale 
Center for 
Epidemiological 
Studies 
Depression 
Scale 
Beck 
Depression 
Inventory-II 
Risk allele LA S S  S LA 
1.4 Brain-Derived Neurotrophic Factor 
Brain-derived neurotrophic factor (BDNF) is a protein involved in neuroplasticity, 
neurogenesis, and memorization (31). Abnormal serum levels of BDNF are associated with several 
neurological conditions, including depression, epilepsy, Alzheimer’s disease, Parkinson’s disease, 
and Huntington’s disease (31). A single-nucleotide polymorphism in the BDNF gene (rs6265, or 
val66met) causes the amino acid methionine to be substituted for valine in the BDNF protein. This 
polymorphism has two alleles, the Met (A) variant allele and the Val (G) wild-type allele (32).  
The Met allele has been associated with higher serum BDNF levels in both healthy subjects 
(32) and subjects who meet criteria for major depression (33). In a study of patients with small-
cell lung cancer, lower serum BDNF levels were associated with more severe depression and 
shorter overall survival. In contrast, higher serum BDNF levels were associated with more mild 
depression and longer overall survival (34). However, once again, studies are inconsistent 
regarding the relationship between rs6265 genotype and depression as both the Val and Met alleles 
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have been implicated as risk factors for the development of depression (35). The study by Rawson 
et al. (2015) examined an interaction between the SERT polymorphism rs25531 and the BDNF 
polymorphism rs6265 and showed an association of the Met/Met genotype with increased 
depressive symptoms, which was only significant in participants with the LA/LA genotype (30). 
1.5 Pathologic Tumor Features 
A study by Koleck et al. (2017) examining pathologic tumor features of women with breast 
cancer showed that certain tumor characteristics were associated with decreased cognitive function 
(36). Another study demonstrated that having high psychoneurological symptoms (anxiety, 
depression, fatigue, etc.) at the time of breast cancer diagnosis predicted clinically relevant 
declines in cognitive function over time (37). Furthermore, cognitive impairment, such as 
difficulty thinking or concentrating, can be a diagnostic symptom of depression (38).  
In this study, tumor stage was an important pathologic tumor feature categorized by early-
stage tumor size: T1a (1-5mm), T1b (5-10mm), T1c (10-20mm), and T2 (20-50mm) (39). Ki67 
classification was another pathologic tumor feature that is a marker for tumor growth and 
classification. Ki67 is an antigen in cell nuclei and its association with cellular proliferation is 
well-established (40). Lastly, HER2 (human epidermal growth factor receptor 2) is a receptor 
protein that is a product of the HER2, or ERBB2, gene. Its overexpression is associated with more 
aggressive disease and poorer prognosis (41-42). 
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2.0 Purpose 
Analysis of the relationship between serotonin transporter and depression in the population 
of women with breast cancer has produced inconsistent results in the literature. In addition, there 
is limited research that examines the serotonin transporter and BDNF genes concurrently and, 
therefore, limited knowledge on the interaction between these genes. Lastly, prior research in 
women with breast cancer has found that pathologic tumor characteristics impact cognitive 
function; however, their impact on depressive symptoms has not been explored. The purpose of 
this study is to investigate an interaction between two biologically relevant genes as well as the 
impact of pathologic tumor characteristics on depressive symptoms in women with breast cancer. 
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3.0 Aims 
The first aim is to characterize the relationship between serotonin transporter (SERT) 
genotype and depressive symptoms in women with breast cancer. The second aim is to examine 
the relationship between BDNF genotype and depressive symptoms, and to analyze the effect of 
any interaction between SERT and BDNF. Lastly, the third aim is to investigate pathologic tumor 
characteristics and their impact on the development of depressive symptoms. 
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4.0 Hypotheses 
Based on results from a University of Pittsburgh School of Nursing study (30), our 
hypothesis for the first aim is that the LA/LA genotype will be associated with increased depressive 
symptoms in the overall sample. For the second aim, our hypothesis is that the Met (A) variant 
allele will be associated with increased depressive symptoms. Lastly, our hypothesis for the third 
aim is that tumor characteristics associated with worse cognitive function will also be associated 
with increased depressive symptoms in women with breast cancer. 
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5.0 Methods 
This study is ancillary from a longitudinal study conducted by University of Pittsburgh 
School of Nursing faculty. In the longitudinal study, depressive symptoms were measured at 
baseline after the breast cancer diagnosis and primary surgery but before the initiation of 
chemotherapy and/or hormonal therapy (anastrozole) for breast cancer participants. They were 
measured again at six months and 12 months post-baseline.  
5.1 Participants 
The longitudinal study was approved by the University of Pittsburgh Institutional Review 
Board and informed consent was obtained from all study participants. Data from a total of N=258 
participants provided samples for genomic evaluation and were included in the analysis for the 
genetic-based objectives of this study. Postmenopausal women with early stage breast cancer 
(n=162) were recruited from the Comprehensive Breast Care Program of the University of 
Pittsburgh Cancer Institute and the University of Pittsburgh Medical Center Cancer Centers. 
Participants were characterized by treatment group, with n=60 subjects receiving both 
chemotherapy and anastrozole and n=102 patients receiving anastrozole only. Due to a small 
sample size of subjects receiving chemotherapy only (n=15), we did not include these subjects in 
statistical analysis. Control group participants (n=96) were healthy postmenopausal women who 
were matched with breast cancer participants on age, IQ, and years of education.  
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For analysis of pathologic tumor feature data, the sample was comprised of n=329 
postmenopausal women with early stage breast cancer recruited from the Comprehensive Breast 
Care Program of the University of Pittsburgh Cancer Institute. Data were collected from surgical 
pathology reports in participants’ medical records. 
All participants were between the ages of 18 and 75 years, could speak and read English, 
and had at least 8 years of education. Demographic information was collected by self-report. 
Exclusion criteria included hospitalization for psychiatric illness within 2 years of study 
enrollment or a history of neurologic disease or cancer. 
5.2 Depressive Symptom Data Collection 
Depressive symptoms, the main dependent variable of interest for this study, was measured 
using the second edition of the Beck Depression Inventory (BDI – II). The BDI – II is a 21-item 
self-report measure in which participants rate depressive symptoms and attitudes on a scale from 
0 (absence of symptom) to 3 (persistent expression of symptom in the past 2 weeks). The overall 
score is a measure of the severity of depressive symptoms, with a score of 14-28 indicating mild 
to moderate depression and a score of 29-63 indicating severe depression. The BDI – II has been 
found to have high internal consistency ranging from α = 0.88 to α = 0.9420.  
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5.3 Genetic Data Collection 
DNA was extracted from either blood or saliva using standard techniques and then 
analyzed for the two SLC6A4 polymorphisms, 5-HTTLPR and rs25531. The two polymorphisms 
of interest were genotyped using a polymerase chain reaction (PCR) restriction fragment length 
polymorphism assay with the following composition from Qiagen Multiplex PCR Kit: 63% Master 
Mix, 6.3% each of the forward and reverse primers, 25% 5Q solution. PCR proceeded with initial 
denaturation at 95°C for 15 min., 35 cycles consisting of 94°C 30 s., 57°C 1 min. 30 s., 72°C 1 
min. 30 s.; final extension step on 72°C 10 min. The sequence of the forward primer was 
CTCCCTGTACCCCTCCTAGG, and the sequence of the reverse primer was 
TGCAAGGAGAATGCTGGAG. The PCR products were then analyzed in 2% agarose gels 
stained with ethidium bromide to genotype 5-HTTLPR. To genotype rs25531, the PCR products 
were digested with 3U of MspI (Fermentas, Canada) according to manufacturer’s 
recommendations and resolved in 2% agarose gels. The digested product for the S-allele was 270 
base pairs, and the digested product for the LA-allele was 300 base pairs. The enzyme cut at the G 
for A substitution in the L allele, indicating the LG-allele if the substitution was present.  
The plan for genotyping the BDNF rs6265 polymorphism originally utilized a TaqMan 
experiment that uses quantitative real-time PCR methodology. This methodology was adapted 
since the assay did not work after multiple attempts despite substantial trouble-shooting. Analysis 
for the BDNF rs6265 polymorphism proceeded with a PCR assay with the following composition: 
56% H2O, 10% buffer (magnesium chloride), 12% DMSO, 16% dNTP, 5% each of the forward 
and reverse primers, and 0.5% Denville Taq polymerase. The assay proceeded as follows: 35 
cycles of 95°C 30 s., 54°C 36 s., 72°C 40 s.; then, 72°C 10 min. The sequence of the forward 
primer was AAACATCCGAGGACAAGGTG and the sequence of the reverse primer was 
 17 
AGAAGAGGAGGCTCCAAAGG. The PCR products were analyzed in 1% agarose gels stained 
with ethidium bromide to check for amplification. To genotype rs6265, enzymatic digestion was 
carried out with 1U of BsaAI according to manufacturer’s recommendations and resolved in 2% 
agarose gels. The enzyme cut at the 124th base pair (G) in the 249-base pair polymorphism. 
Genotype was determined by bands created by migration of DNA fragments in the gel. Met/Met 
(A/A) genotype was indicated by a longer fragment (negative digestion), Val/Val (G/G) genotype 
was indicated by a shorter fragment (positive digestion), and Met/Val (A/G) genotype was 
indicated by two fragments.  
5.4 Pathologic Tumor Feature Data Collection 
Pathologic tumor feature data were obtained from the Koleck et al. (2017) study, which 
was ancillary to another University of Pittsburgh School of Nursing study. Both studies were 
approved by the University of Pittsburgh Institutional Review Board. The sample of N=329 
participants was comprised of postmenopausal women with early stage breast cancer recruited 
from the Comprehensive Breast Care Program of the University of Pittsburgh Cancer Institute. 
Inclusion and exclusion criteria were the same as discussed above. Data were collected from 
surgical pathology reports in participants’ medical records.   
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5.5 Statistical Analysis 
During exploratory analysis, we found that the BDI-II scores showed a right-skewed 
distribution (i.e., the majority of women reported minimal depressive symptoms) in both samples. 
We performed statistical analysis treating the BDI-II score both as a continuous variable and as a 
binary variable according to no depressive symptoms vs. some depressive symptoms, as well as 
minimal depression vs. moderate or greater depression. Score ranges for BDI-II categories were 
established as follows: minimal (0-13), mild (14-19), moderate (20-28), and severe (29-63).  
To determine associations between genetic and tumor feature variables with depressive 
symptoms, ANOVA, correlation, and and chi-square/Fisher’s exact test analyses were performed 
at each time point. Unadjusted and adjusted linear and logistic regression models were then 
generated with and without control for treatment group (i.e., chemotherapy/anastrozole or 
anastrozole only) as a predictor. Unstandardized beta coefficients and two-tailed significance tests 
were used to determine statistical significance. All analyses were performed using IBM SPSS 
Statistics 25.0 with a statistical significance level of α = 0.05. The results that are ultimately 
presented are from linear regression models adjusted for treatment group with main effects only. 
5.5.1  Aim 1: SERT Genotype and BDI-II Score and Aim 2: BDNF Genotype and BDI-II 
Score 
Demographic characteristics for the N=258 participants included in genetic analysis 
consisted of means, standard deviations, medians, minima, and maxima for continuous variables, 
as well as frequencies for categorical variables. These characteristics were computed for the 
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overall sample and by cohort. Statistical significance to identify differences between treatment 
groups was determined by ANOVA or Fisher’s exact tests.  
SERT genotype was categorized into three groups for statistical analysis, with the LG-allele 
being treated as functionally equivalent to the S-allele. Thus, SERT genotypes were compared 
according to LA vs. LA/LG +S/LA vs. S+S/LG + LG. The binary model compared LA (high serotonin 
activity) vs. all other genotypes. An additive model was included to treat SERT genotype as a 
continuous predictor for depressive symptoms, both with and without treatment group predictors. 
Genotype frequencies were calculated by cohort and for the overall sample. Boxplots were 
constructed to compare BDI-II scores by SERT genotype across all timepoints, allowing BDI-II 
score outliers to be identified. In addition, we added interaction terms to regression models 
analyzing BDI-II score by treatment cohort and SERT genotype.  
Genotype frequencies for BDNF were also calculated by cohort and for the overall sample. 
BDNF genotypes were compared individually according to Val/Val vs. Met/Val vs. Met/Met, and 
in two groups according to Val/Val vs. at least one Met allele. An additive model was created to 
examine BDNF genotype as a continuous predictor for depressive symptoms, both with and 
without treatment group predictors.  
5.5.2  Aim 3: Pathologic Tumor Features and BDI-II Score 
Demographic characteristics and pathologic tumor feature data for the N=329 participants 
consisted of means, standard deviations, medians, minima, and maxima for continuous variables, 
as well as frequencies for categorical variables. These characteristics were computed for the 
overall sample and by cohort. Statistical significance to identify differences between treatment 
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groups was determined by t-tests for equality of means (equal variances not assumed) and Fisher’s 
exact tests.  
We conducted additional analyses on tumor stage. Specifically, we performed ANOVA to 
compare age and years of education between participants with different tumor stages. We created 
spaghetti plots using R to visualize the trajectory of BDI-II scores over time by tumor stage and 
treatment group for each participant. In response, a follow-up sensitivity analysis was conducted 
to evaluate potential influential points. 
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6.0 Results 
Table 2 Descriptive Statistics for BDI-II Score in the Genetic-Based Sample (N=258) 
 Baseline 6-months 12-months 
 Overall Overall Overall 
Mean 
(SD) 
4.83 (4.87) 5.72 (5.88) 5.28 (5.87) 
Median 4 4 4 
 Chemo 
+ 
Anast 
Anast 
Only 
Healthy 
Control 
Chemo 
+ 
Anast 
Anast 
Only 
Healthy 
Control 
Chemo 
+ 
Anast 
Anast 
Only 
Healthy 
Control 
Mean 5.08 4.65 4.85 8.02 5.37 4.63 5.63 5.83 4.47 
Median 5 4 3 7 3 3 5 4 3 
 
Table 3 Descriptive Statistics for BDI-II Score in the Pathologic Tumor Features Sample (N=329) 
 Baseline 6-months 12-months 
 Overall Overall Overall 
Mean 
(SD) 
5.33 (5.62) 6.08 (6.09) 5.79 (6.60) 
Median 4 5 4 
 Chemo + 
Anast 
Anast 
Only 
Chemo + 
Anast 
Anast Only Chemo + 
Anast 
Anast 
Only 
Mean 5.88 5.03 7.32 5.03 5.54 5.94 
Median 4 4 6 4 5 4 
 
Table 4 BDI-II Score Categories in the Genetic-Based Sample (N=258) 
 N (%) 
 Baseline 6-months 12-months 
Minimal depression 239 (93.4%) 235 (91.8%) 208 (92.4%) 
Moderate or higher 
depression 
17 (6.6%) 21 (8.2%) 17 (7.6%) 
 
Table 5 BDI-II Score Categories in the Pathologic Tumor Features Sample (N=329) 
 N (%) 
 Baseline 6-months 12-months 
Minimal depression 299 (90.9%) 243 (90.7%) 176 (91.2%) 
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Moderate or higher 
depression 
30 (9.1%) 25 (9.3%) 17 (8.8%) 
 
Table 6 Characteristics of Patients Included in Genetic Analysis, Overall Sample (N=258) 
Characteristic Mean (SD), 
Median or n 
(%) 
Minimum Maximum 
Age (years) 60.16 (6.20), 
60 
43 75 
Education (years) 15.20 (2.99), 
15 
9 29 
Marital Status (currently 
married or living with 
significant other) 
 
169 (65.5) 
NA NA 
Number of Children 1.99 (1.37), 2 0 8 
Race (Caucasian) 245 (95.0) NA NA 
 
Table 7 Characteristics of Patients Included in Genetic Analysis By Cohort 
 Chemotherapy/Anastrozo
le (n=60) 
Anastrozole Only 
(n=102) 
Healthy Controls 
(n=96) 
p-value 
Characteristi
c 
Mean 
(SD), 
Median 
or n (%) 
Min. Max. Mean 
(SD), 
Median 
or n (%) 
Min. Max. Mean 
(SD), 
Median 
or n (%) 
Min. Max.  
Age (years) 59.00 
(5.59), 59 
47 71 62.35 
(5.86), 
62.5 
51 75 58.54 
(6.28), 59 
43 74 <0.001 
Education 
(years) 
15.65 
(2.76), 16 
12 22 14.80 
(2.93), 14 
9 26 15.33 
(3.18), 16 
11 29 0.189 
Marital 
Status 
(currently 
married or 
living with 
significant 
other) 
42 (70.0) NA NA 70 (68.6) NA NA 57 (59.4) NA NA 0.295 
Number of 
Children 
1.70 
(1.21), 2 
0 5 2.08 
(1.33), 2 
0 7 2.08 
(1.48), 2 
0 8 0.168 
Race 
(Caucasian) 
57 (95.0) NA NA 99 (97.1) NA NA 89 (92.7) NA NA 0.39 
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Table 8 SERT Genotypes 
 Chemotherapy/Anastrozole 
(n=60) 
N (%) 
Anastrozole 
Only (n=102) 
N (%) 
Healthy 
controls 
(n=96) 
N (%) 
Total sample 
(n=258) 
N (%) 
S/S 11 (18.3) 19 (18.6) 22 (22.9) 52 (20.1) 
S/LG 4 (6.7) 5 (4.9) 7 (7.2) 16 (6.2) 
S/LA 25 (41.6) 42 (41.1) 42 (43.7) 109 (42.2) 
LA/LG 4 (6.7) 4 (3.9) 6 (6.2) 14 (5.4) 
LA/LA 16 (26.7) 31 (30.3) 19 (19.7) 66 (25.6) 
LG/LG 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.3) 
 
Table 9 BDNF Genotypes 
 Chemotherapy/Anastrozole 
(n=60) 
N (%) 
Anastrozole 
Only (n=102) 
N (%) 
Healthy 
controls 
(n=96) 
N (%) 
Total 
sample 
(n=258) 
N (%) 
Met/Met 
(A/A) 
3 (5.0) 8 (7.8) 7 (7.2) 18 (6.9) 
Met/Val 
(A/G) 
18 (30.0) 42 (41.1) 34 (35.4) 94 (36.4) 
Val/Val 
(G/G) 
39 (65.0) 52 (50.9) 55 (57.2) 146 (56.5) 
 
Table 10 Characteristics of Patients Included in Pathologic Tumor Feature Analysis, Overall Sample (N=329) 
Characteristic Mean (SD), 
Median 
or n (%) 
Minimum Maximum 
Age (years) 61.05 (5.98), 
61 
45 75 
Education (years) 14.80 (2.81), 
14 
6 26 
Marital Status (currently 
married or living with 
significant other) 
223 (67.8) NA NA 
Number of Children 1.89 (1.24), 2 0 7 
Race (Caucasian) 317 (96.4) NA NA 
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Table 11 Characteristics of Patients Included in Pathologic Tumor Feature Analysis By Cohort 
 Chemotherapy/Anastrozo
le (n=117) 
Anastrozole Only 
(n=212) 
p-value 
Characteristic Mean 
(SD), 
Median 
or n (%) 
Min. Max. Mean 
(SD), 
Median 
or n (%) 
Min. Max.  
Age (years) 59.45 
(5.20), 60 
47 71 61.92 
(6.20), 61 
45 75 <0.001 
Education (years) 14.89 
(2.92), 14 
6 23 14.75 
(2.75), 14 
9 26 0.663 
Marital Status (currently 
married or living with 
significant other) 
81 (69.2) NA NA 142 (67.0) NA NA 0.713 
Number of Children 1.85 
(1.23), 2 
0 5 1.91 
(1.25), 2 
0 7 0.695 
Race (Caucasian) 111 (94.9) NA NA 206 (97.2) NA NA 0.359 
 
Table 12 Pathologic Tumor Features, Overall Sample 
Tumor Characteristics Mean (SD), 
Median  
or n (%) 
Minimum Maximum n 
AJCC Tumor Stage 
Stage I 
Stage IIA 
Stage IIB 
Stage IIIA 
 
214 (65.0) 
75 (22.8) 
24 (7.3) 
16 (4.9) 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
329 
Tumor Size (cm) 1.66 (1.50), 1.30 0.1 14 328 
Aggregate Tumor Size (cm) 1.80 (1.60), 1.40 0.1 14 328 
Tumor Classification  
T1a 
T1b 
T1c 
T2 
T3 
 
37 (11.2) 
82 (24.9) 
133 (40.4) 
65 (19.8) 
12 (3.6) 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
329  
Lymph Node 
Positive 
Negative 
 
73 (22.5) 
252 (77.5) 
 
NA 
NA 
 
NA 
NA 
325 
 
Number of Positive Nodes 0.42 (1.05), 0 0 8 329 
Tumor Focality/Centricity 
Single 
Multiple 
 
277 (84.2) 
52 (15.8) 
 
NA 
NA 
 
NA 
NA 
329 
 
Tumor Laterality    329 
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Right breast 
Left breast 
149 (45.3) 
180 (54.7) 
NA 
NA 
NA 
NA 
Tumor Location Octant 
Upper outer 
Lower outer 
Lower inner 
Upper inner 
Upper junction 
Lower junction 
Outer junction 
Inner junction 
Retroareolar 
 
125 (38.7) 
28 (8.7) 
21 (6.5) 
42 (13.0) 
38 (11.8) 
17 (5.3) 
30 (9.3) 
9 (2.8) 
13 (4.0) 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
323 
Tumor Location Quadrant 
Upper outer 
Lower outer 
Lower inner 
Upper inner 
Retroareolar 
 
163 (50.5) 
58 (18.0) 
38 (11.8) 
51 (15.8) 
13 (4.0) 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
323 
Invasive Type 
Ductal 
Lobular 
Ductal & Lobular 
 
285 (86.9) 
35 (10.7) 
8 (2.4) 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
328 
Nottingham Score 6.04 (1.31), 6 3 9 315 
Nottingham Grade 
Grade 1 
Grade 2 
Grade 3 
 
95 (30.1) 
171 (54.1) 
50 (15.8) 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
316 
ER Status 
Positive  
Negative 
 
324 (98.8) 
4 (1.2) 
 
NA 
NA 
 
NA 
NA 
328 
ER H-Score 256.90 (59.98), 
280 
0 300 311 
PR Status 
Positive 
Negative 
 
288 (87.8) 
40 (12.2) 
 
NA 
NA 
 
NA 
NA 
328 
PR H-Score 130.08 (101.30), 
130 
0 300 310 
HER2 Status 
Positive 
Negative 
 
28 (8.8) 
290 (91.2) 
 
NA 
NA 
 
NA 
NA 
318 
HER2 IHC Score 1.21 (0.87), 1 0 3 291 
LV Invasion 
Present 
Absent 
 
68 (21.1) 
255 (78.9) 
 
NA 
NA 
 
NA 
NA 
323 
KI67 Classification 
Low 
 
66 (39.1) 
 
NA 
 
NA 
169 
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Moderate 
High 
Very High 
50 (29.6) 
34 (20.1) 
19 (11.2) 
NA 
NA 
NA 
NA 
NA 
NA 
KI67 Index 23.10 (21.52), 15 1 90 168 
Oncotype DX Recurrence 
Score 
18.26 (9.76), 18 0 63 160 
 
 
Table 13 Pathologic Tumor Features By Cohort 
 Chemotherapy/Anastrozole  Anastrozole Only (n=212) p-value 
Tumor Characteristics Mean (SD), 
Median 
or n (%) 
Min. Max. n Mean (SD), 
Median 
or n (%) 
Min. Max. n  
AJCC Tumor Stage 
Stage I 
Stage IIA 
Stage IIB 
Stage IIIA 
 
43 (36.8) 
41 (35.0) 
17 (14.5) 
16 (13.7) 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
117 
 
 
 
 
171 (80.7) 
34 (16.0) 
7 (3.3) 
0 (0) 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
212 <0.001 
Tumor Size (cm) 2.32 (1.91), 
1.80 
0.4 14 117 1.30 (1.06), 
1.10 
0.1 10 211 <0.001 
Aggregate Tumor Size 
(cm) 
2.50 (2.00), 
1.90 
0.4 14 117 1.41 (1.17), 
1.10 
0.1 10 211 <0.001 
Tumor Classification  
T1a 
T1b 
T1c 
T2 
T3 
 
2 (1.7) 
19 (16.2) 
48 (41.0) 
38 (32.5) 
10 (8.5) 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
117 
 
 
35 (16.5) 
63 (29.7) 
85 (40.1) 
27 (12.7) 
2 (0.9) 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
212 <0.001 
Lymph Node 
Positive 
Negative 
 
62 (53.0) 
55 (47.0) 
 
NA 
NA 
 
NA 
NA 
117  
18 (8.7) 
190 (91.3) 
 
NA 
NA 
 
NA 
NA 
208 <0.001 
Number of Positive 
Nodes 
1.01 (1.55), 
0 
0 8 117 0.10 
(0.344), 0 
0 2 212 <0.001 
Tumor 
Focality/Centricity 
Single 
Multiple 
 
 
98 (83.8) 
19 (16.2) 
 
 
NA 
NA 
 
 
NA 
NA 
117 
 
 
 
179 (84.4) 
33 (15.6) 
 
 
NA 
NA 
 
 
NA 
NA 
212 0.876 
Tumor Laterality 
Right breast 
Left breast 
 
47 (40.2) 
70 (59.8) 
 
NA 
NA 
 
NA 
NA 
117  
102 (48.1) 
110 (51.9) 
 
NA 
NA 
 
NA 
NA 
212 0.203 
Tumor Location Octant 
Upper outer 
Lower outer 
Lower inner 
Upper inner 
 
44 (38.3) 
9 (7.8) 
6 (5.2) 
19 (16.5) 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
115  
81 (38.9) 
19 (9.1) 
15 (7.2) 
23 (11.1) 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
208 0.915 
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Upper junction 
Lower junction 
Outer junction 
Inner junction 
Retroareolar 
11 (9.6) 
6 (5.2) 
12 (10.4) 
3 (2.6) 
5 (4.3) 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
27 (13.0) 
11 (5.3) 
18 (8.7) 
6 (2.9) 
8 (3.8) 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Tumor Location 
Quadrant 
Upper outer 
Lower outer 
Lower inner 
Upper inner 
Retroareolar 
 
 
55 (47.8) 
21 (18.3) 
12 (10.4) 
22 (19.1) 
5 (4.3) 
 
 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
NA 
115  
 
108 (51.9) 
37 (17.8) 
26 (12.5) 
29 (13.9) 
8 (3.8) 
 
 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
NA 
208 0.76 
Invasive Type 
Ductal 
Lobular 
Ductal & Lobular 
 
106 (90.6) 
11 (9.4) 
0 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
117  
179 (84.4) 
24 (11.4) 
8 (3.8) 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
211 <0.001 
Nottingham Score 6.71 (1.32), 
6 
4 9 117 5.66 (1.13), 
6 
3 9 199 0.075 
Nottingham Grade 
Grade 1 
Grade 2 
Grade 3 
 
18 (15.4) 
60 (51.3) 
39 (33.3) 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
117  
77 (38.7) 
111 (55.8) 
11 (5.5) 
 
NA 
NA 
NA 
 
NA 
NA 
NA 
199 <0.001 
ER Status 
Positive  
Negative 
 
113 (96.6) 
4 (3.4) 
 
NA 
NA 
 
NA 
NA 
117  
211 (100) 
0 (0) 
 
NA 
NA 
 
NA 
NA 
211 0.016 
ER H-Score 237.73 
(79.13), 
270 
0 300 112 267.68 
(42.40), 
280 
80 300 199 0.001 
PR Status 
Positive 
Negative 
 
93 (79.5) 
24 (20.5) 
 
NA 
NA 
 
NA 
NA 
117  
195 (92.4) 
16 (7.6) 
 
NA 
NA 
 
NA 
NA 
211 0.001 
PR H-Score 104.71 
(101.17), 
91 
0 300 112 267.68 
(42.40), 
280 
80 300 199 0.001 
HER2 Status 
Positive 
Negative 
 
19 (16.2) 
94 (83.2) 
 
NA 
NA 
 
NA 
NA 
113  
9 (4.4) 
196 (95.6) 
 
NA 
NA 
 
NA 
NA 
205 <0.001 
HER2 IHC Score 1.47 (0.89), 
1 
0 3 107 1.07 (0.82), 
1 
0 3 184 <0.001 
LV Invasion 
Present 
Absent 
 
47 (40.9) 
68 (59.1) 
 
NA 
NA 
 
NA 
NA 
115  
21 (10.1) 
187 (89.9) 
 
NA 
NA 
 
NA 
NA 
208 <0.001 
KI67 Classification 
Low 
Moderate 
 
19 (31.7) 
15 (25.0) 
 
NA 
NA 
 
NA 
NA 
60  
47 (43.1) 
35 (32.1) 
 
NA 
NA 
NA
NA 
109 0.004 
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High 
Very High 
12 (20.0) 
14 (23.3) 
NA 
NA 
NA 
NA 
22 (20.2) 
5 (4.6) 
NA
NA 
NA 
NA 
KI67 Index 31.62 
(27.03), 
22.5 
2 90 60 18.37 
(16.03), 15 
1 80 18 0.001 
Oncotype DX 
Recurrence Score 
26.82 
(10.09), 25 
9 63 49 14.48 
(6.79), 15 
0 29 111 <0.001 
 
Using the three-group comparison (LA vs. LA/LG +S/LA vs. S+S/LG + LG), we found that 
participants with one copy of the LA-allele had lower BDI-II scores at baseline (b=-1.641, 
p=0.029; x̄=4.27, SD=4.1, Median=3.5), six months (b=-1.84, p=0.038; x̄=4.96, SD=4.72, 
Median=3.5), and 12 months (b=-2.276, p=0.017; x̄=4.51, SD=4.49, Median=4) compared to 
participants homozygous for the LA-allele (baseline: x̄=5.88, SD=5.76, Median=4.5; 6-months: 
x̄=6.89, SD=6.44, Median=5; 12-months: x̄=6.93, SD=7.33, Median=5). A similar trend was noted 
for participants with no LA-alleles at baseline (b=-1.129, p=0.182; x̄=4.79, SD=5.08, Median=3), 
six months (b=-0.793, p=0.426; x̄=5.93, SD=6.94, Median=4), and 12 months (b=-1.775, 
p=0.101; x̄=5.01, SD=6.22, Median=3) compared to participants homozygous for the LA-allele. 
Using the comparison of LA vs. all other genotypes, we again found that participants homozygous 
for the LA-allele had higher BDI-II scores at baseline (b=-1.459, p=0.037; x̄=5.88, SD=5.76, 
Median=4.5) and at 12 months post-baseline (b=-2.098, p=0.019; x̄=6.93, SD=7.33, Median=5) 
compared to all other genotypes (baseline: x̄=4.46, SD=4.47, Median=3; 12 months: x̄=4.69, 
SD=5.16, Median=3).  
There were no statistically significant differences in mean BDI-II score between subjects 
with the different BDNF genotypes throughout the study. Subjects with at least one Met allele had 
consistently higher mean BDI-II scores at all timepoints (baseline: x̄=4.91, SD=5.04, Median=4; 
6-months: x̄=5.9, SD=6.19, Median=4; 12-months: x̄=5.48, SD=5.82, Median=4) compared to 
subjects with Val/Val (baseline: x̄=4.76, SD=4.73, Median=3; 6-months: x̄=5.57, SD=5.63, 
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Median=4; 12-months: x̄=5.12, SD=5.93, Median=4) though these differences were not 
significant. In addition, the additive model for BDNF genotype as a predictor for depressive 
symptoms was not significant.  
At baseline, a high Ki67 classification was associated with fewer depressive symptoms 
(b=-2.543, p=0.035; x̄=3.88, SD=3.78, Median=3) compared to a low Ki67 classification (x̄=6.36, 
SD=5.88, Median=5) At six months post-baseline, a multifocal tumor (b=2.479, p=0.012; x̄=8.09, 
SD=9.36, Median=5) was associated with increased depressive symptoms compared to a single 
focus tumor (x̄=5.68, SD=5.14, Median=5). Also at six months post-baseline, as HER2 
classification score increased (b=1.079, p=0.02), BDI-II score increased. At 12 months post-
baseline, tumor stage was a significant predictor of depressive symptoms. Subjects with tumor 
stages T1b (b=-3.669, p=0.029; x̄=5.15, SD=5.07, Median=4), T1c (b=-3.292, p=0.041; x̄=5.56, 
SD=5.66, Median=4), and T2 (b=-3.762, p=0.036; x̄=5.12, SD=4.9, Median=3.5) had 
significantly lower BDI-II scores compared to subjects with T1a (x̄=8.79, SD=12, Median=4). At 
face value, this suggests that patients with an earlier tumor stage experience increased depressive 
symptoms. HER2-positive subjects had higher BDI-II scores (baseline: x̄=6.64, SD=6.89, 
Median=5; 6-months: x̄=8.91, SD=9.48, Median=6.5; 12-months: x̄=7.06, SD=10.77, 
Median=4.5) than HER2-negative subjects (baseline: x̄=5.28, SD=5.53, Median=4; 6-months: 
x̄=5.85, SD=5.64, Median=5; 12-months: x̄=5.68, SD=6.17, Median=4) across all three 
timepoints, but these differences were not statistically significant. 
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7.0 Discussion 
The significant association between the LA-allele and increased depressive symptoms in 
this study is consistent with the previous study conducted by University of Pittsburgh School of 
Nursing faculty with a smaller sample size (n=125). Our results suggest that the LA-allele may be 
a risk allele for depressive symptoms in women with breast cancer and healthy controls. However, 
the converse is not supported by the data; in other words, having no copies of the LA-allele was 
not a protective factor. Interestingly, there was not a significant difference in depressive 
symptomology between the group with two copies of the LA-allele and the group with no copies 
of the LA-allele. This may suggest that an extreme in serotonin transporter activity in either 
direction (high or low) may be a risk factor for the development of depressive symptoms. Another 
possible explanation is that SERT genotype alone is not a reliable predictor of depressive 
symptoms and that there may be epigenetic influences involved. Lastly, mean BDI-II scores for 
all groups at all timepoints fall within the category of minimal depression, so differences may not 
be clinically significant.  
Although there is evidence in the literature for associations between BDNF genotype and 
serum BDNF level, as well as between serum BDNF level and depressive symptoms, it seems 
more difficult to ascertain a relationship, if any exists, between BDNF genotype and depression. 
For example, in a study of patients receiving treatment for depression, there was a significant 
relationship between having at least one Met allele and having higher plasma BDNF levels. 
However, neither genotype nor plasma BDNF level were significantly associated with depressive 
symptoms or response to treatment, suggesting that these biological characteristics carry limited 
clinical implications for patients (43). Our study is consistent with this finding as well as with 
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another study of healthy older adults, in which no association was found between BDNF genotype 
and mood status, including depression (44). It is likely that the relationship between BDNF 
genotype and depression involves other factors that require further investigation, such as gender 
(35, 45), promoter methylation (46), other candidate genes, and negative life events (47).  
There were no pathologic tumor features that were significantly associated with depressive 
symptoms across all three timepoints. We hypothesized that a possible difference in age among 
subjects with T1a compared to subjects with more advanced tumor stages could have contributed 
to the difference seen in severity of depressive symptoms. However, further testing showed that 
subjects of the different tumor stages did not differ significantly in age or years of education. 
Spaghetti plots allowed us to identify two subjects in the anastrozole-only group with stage T1a 
tumors and BDI-II scores at 12 months post-baseline categorized as severe (score > 28). Follow-
up influential point regression analysis excluding these two subjects did not result in statistical 
significance, indicating that our original result was a direct effect of these two influential points. 
Thus, we cannot conclude any association between tumor stage and depressive symptoms in 
women with breast cancer.  
However, our results are similar to those demonstrated in the Koleck et al. (2017) study 
even though they were not constant over time. Koleck et al. (2017) demonstrated that having a 
tumor with a moderate Ki67 classification contributed more favorably to cognitive function than 
a low classification. Similarly, we found that a high classification was associated with fewer 
depressive symptoms compared to a low classification. A study of the basolateral complex of the 
amygdala in rats found a negative relationship between cellular proliferation (measured by an 
assay for Ki67 expression) and depression-like behavior, modulated by anxiety level, which could 
support an association between increased Ki67 expression and reduced depressive symptoms (48). 
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Subjects with multifocal tumors and increased HER2 classification had higher depressive 
symptoms, which is consistent with associations between these features and poorer cognitive 
performance. In addition to HER2 receptor, the family of ERBB genes encodes for receptor 
tyrosine kinases, which are activated by proteins called neuregulins (NRG). The network of NRG-
ERBB interactions has been implicated in nervous system development and has also been proposed 
to influence psychiatric disorders such as schizophrenia, bipolar disorder, and depression (41). 
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8.0 Limitations 
A main limitation of this study was a lack of variability in BDI-II score, with the majority 
of participants having minimal depressive symptoms. After categorizing participants into 
clinically meaningful groups by BDI-II score to mitigate the effect of the skew, our groups were 
still unevenly distributed. In this way, we chose to treat BDI-II score as a continuous variable. 
Another limitation is that the chemotherapy-only cohort of participants with breast cancer was not 
included in analysis due to a small sample size (n=15). In addition, exclusion criteria for 
participation did not include pre-morbid depression and this may have contributed to the few 
influential points and high BDI-II scores identified during follow-up analysis.  
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